{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:44:07Z","timestamp":1778906647134,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"DOI":"10.7759\/cureus.57024","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:03:34Z","timestamp":1711533814000},"source":"Crossref","is-referenced-by-count":2,"title":["Atezolizumab-Induced Type 1 Diabetic Ketoacidosis in a Patient With Small Cell Lung Cancer and Pre-existing Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Kohei","family":"Narumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reo","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110414","article-title":"Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus","volume":"122","author":"Liao D","year":"2023","unstructured":"Liao D, Liu C, Chen S, Liu F, Li W, Shangguan D, Shi Y. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. Int Immunopharmacol. 2023, 122:110414. 10.1016\/j.intimp.2023.110414","journal-title":"Int Immunopharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032076","article-title":"Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: a case report","volume":"101","author":"Wen YP","year":"2022","unstructured":"Wen YP, Xiao HW, Yin JH, Guo HR, Shan MJ, Shen LP, Liu LS. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: a case report. Medicine (Baltimore). 2022, 101:e32076. 10.1097\/MD.0000000000032076","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025795","article-title":"Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: a case report and literature review","volume":"100","author":"Huang X","year":"2021","unstructured":"Huang X, Yang M, Wang L, Li L, Zhong X. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: a case report and literature review. Medicine (Baltimore). 2021, 100:e25795. 10.1097\/MD.0000000000025795","journal-title":"Medicine (Baltimore)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al.. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018, 379:2220-9. 10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares L","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al.. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019, 394:1929-39. 10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal A","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019, 7:e000591. 10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101473","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus","volume":"24","author":"Liu J","year":"2022","unstructured":"Liu J, Shi Y, Liu X, et al.. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus. Transl Oncol. 2022, 24:101473. 10.1016\/j.tranon.2022.101473","journal-title":"Transl Oncol"},{"key":"ref8","article-title":"Management of immunotherapy-related toxicities, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson JA","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. Management of immunotherapy-related toxicities, NCCN Clinical Practice Guidelines in Oncology. JNCCN. 2022, 20:[Epub].","journal-title":"JNCCN"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05666-w","article-title":"When therapeutic drugs lead to diabetes","volume":"65","author":"F\u00e8ve B","year":"2022","unstructured":"F\u00e8ve B, Scheen AJ. When therapeutic drugs lead to diabetes. Diabetologia. 2022, 65:751-62. 10.1007\/s00125-022-05666-w","journal-title":"Diabetologia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani K","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, et al.. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018, 4:374-8. 10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100074","article-title":"Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1\/programmed death-ligand 1 blockade in SCLC","volume":"1","author":"Ricciuti B","year":"2020","unstructured":"Ricciuti B, Naqash AR, Naidoo J, et al.. Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1\/programmed death-ligand 1 blockade in SCLC. JTO Clin Res Rep. 2020, 1:100074. 10.1016\/j.jtocrr.2020.100074","journal-title":"JTO Clin Res Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13065","article-title":"Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: a case report","volume":"10","author":"Edahiro R","year":"2019","unstructured":"Edahiro R, Ishijima M, Kurebe H, et al.. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: a case report. Thorac Cancer. 2019, 10:1276-9. 10.1111\/1759-7714.13065","journal-title":"Thorac Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al.. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020, 6:865-71. 10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241410-atezolizumab-induced-type-1-diabetic-ketoacidosis-in-a-patient-with-small-cell-lung-cancer-and-pre-existing-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:03:37Z","timestamp":1711533817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241410-atezolizumab-induced-type-1-diabetic-ketoacidosis-in-a-patient-with-small-cell-lung-cancer-and-pre-existing-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.57024","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}